The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Radioiodine (RAI) in combination with durvalumab for recurrent/metastatic thyroid cancers.
 
Bharat Burman
Employment - Janssen (I)
Stock and Other Ownership Interests - Janssen (I)
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Cota Healthcare; Eisai; Goldilocks; Lilly; Regeneron; UpToDate
Research Funding - Plexxikon
 
Anuja Kriplani
No Relationships to Disclose
 
Loren S. Michel
Research Funding - Exelixis (Inst)
Travel, Accommodations, Expenses - Immunomedics
 
Lara Dunn
Consulting or Advisory Role - CUE Biopharma; CUE Biopharma; Regeneron
Research Funding - Eisai; Pfizer; Regeneron
 
James Vincent Fetten
No Relationships to Disclose
 
Elizabeth Warner
No Relationships to Disclose
 
Ravinder K Grewal
No Relationships to Disclose
 
Mona Sabra
Speakers' Bureau - Eisai
 
R. Michael Tuttle
Honoraria - Roche
Consulting or Advisory Role - Loxo; Roche; Sanofi
 
Laura Boucai
No Relationships to Disclose
 
Stephanie Fish
No Relationships to Disclose
 
Sofia Haque
Honoraria - Advance Medical
Consulting or Advisory Role - Advance Medical
 
Irina Ostrovnaya
No Relationships to Disclose
 
Ronald A Ghossein
Employment - Veracyte
Honoraria - Veracyte
 
Jeffrey Knauf
No Relationships to Disclose
 
David G. Pfister
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Incyte
Research Funding - AstraZeneca; Atara Biotherapeutics; Bayer (Inst); Boehringer Ingelheim; Eisai (Inst); Exelixis; Genentech/Roche (Inst); Lilly (Inst); MedImmune; Merck; Novartis; Regeneron
 
James A Fagin
Consulting or Advisory Role - Loxo
Patents, Royalties, Other Intellectual Property - Kura Oncology
 
Alan Loh Ho
Consulting or Advisory Role - AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; CureVac; CureVac; Eisai; Genzyme; Merck; Novartis; Regeneron; Sanofi; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Novartis; Omniprex America
Research Funding - Allos Therapeutics; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Ayala Pharmaceuticals; Ayala Pharmaceuticals; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevar Therapeutics; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly; Merck; Novartis; Novartis; Novartis; Pfizer
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Ignyta; Janssen Oncology; Klus Pharma; Kura Oncology; Kura Oncology; Kura Oncology; Merck